title: Adaptation and validation of the Urticaria Patient Daily Diary for adolescents.
abstract: The Urticaria Patient Daily Diary, including the Urticaria Activity Score, has recently been validated in adults with chronic idiopathic urticaria (CIU), but its validity in adolescents is unknown. This study was designed to (1) assess the content validity of the Adolescent Urticaria Patient Daily Diary and, (2) collect exploratory data on symptom experiences, sleep interference, and health-related quality of life (HRQOL) of adolescents with CIU. The Urticaria Patient Daily Diary was modified to increase its relevance with an adolescent population. A qualitative, cross-sectional, multicenter study was then conducted in the United States so that adolescent subjects could provide information on the impact of urticaria on their lives and comment on the diary. Data were collected via in-person semistructured interviews with subjects 12-17 years of age with moderate-to-severe CIU. The most bothersome symptom was itching (44%). The impact of CIU on HRQOL varied. The majority of subjects (78%) reported waking up at least once a night. Overall, subjects found the diary to be clear, easy to comprehend, and easy to complete. Revisions were made to the diary based on feedback from subjects. After nine interviews, no new information was received. The symptoms of CIU are bothersome to adolescents, particularly itch, and urticaria has a negative impact on the sleep of adolescent patients. The final Adolescent Urticaria Patient Daily Diary has evidence of content validity in patients with CIU ranging from 12 to 17 years of age.
authors.affiliation: Health Outcomes Solutions, Winter Park, Florida, USA. smathias@healthoutcomessolutions.com
authors.forename: Susan D
authors.initials: SD
authors.lastname: Mathias
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Tschosik
authors.forename: James L
authors.initials: JL
authors.lastname: Zazzali
mesh_terms: D000293:Adolescent; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D017332:Cetirizine / Q000627:therapeutic use; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use; D006801:Humans; D007407:Interviews as Topic; D008297:Male; D017063:Outcome Assessment, Health Care; D011537:Pruritus / Q000188:drug therapy / Q000523:psychology*; D011788:Quality of Life / Q000523:psychology*; D018434:Sickness Impact Profile; D013223:Statistics as Topic; D016593:Terfenadine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States; D014581:Urticaria / Q000188:drug therapy / Q000523:psychology*
chemical_list: D018926:Anti-Allergic Agents; D039563:Histamine H1 Antagonists, Non-Sedating; D016593:Terfenadine; C093230:fexofenadine; D017332:Cetirizine